# Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree
Canonical URL: https://biopharmsignal.com/news/AQST/aquestive-therapeutics-completes-150-million-debt-refinancing-with-oaktree
Ticker: AQST
Company: Aquestive Therapeutics
Source: Aquestive Therapeutics
Published: 2026-05-12 13:32 EST
Original Source URL: https://investors.aquestive.com
## Summary

WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the

## Article Body
WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the
## Recent Company News
- 2026-05-13 20:01 EST — [Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/AQST/aquestive-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Aquestive Therapeutics
- 2026-05-12 13:32 EST — [Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree](https://biopharmsignal.com/news/AQST/aquestive-therapeutics-completes-150-million-debt-refinancing-with-oaktree) — Source: Aquestive Therapeutics
- 2026-05-06 11:00 EST — [Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET](https://biopharmsignal.com/news/AQST/aquestive-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-business-highlights-on-may-13-and-host-conference-call-on-may-14-at-8-00-a-m-et) — Source: Aquestive Therapeutics
- 2026-03-30 11:00 EST — [Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film](https://biopharmsignal.com/news/AQST/aquestive-therapeutics-announces-completion-of-type-a-meeting-with-fda-for-anaphylmtm-dibutepinephrine-sublingual-film) — Source: Aquestive Therapeutics
- 2026-03-20 11:00 EST — [Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer](https://biopharmsignal.com/news/AQST/aquestive-therapeutics-announces-new-role-of-lori-j-braender-and-appointment-of-thomas-a-zalewski-as-chief-legal-officer-and-chief-compliance-officer) — Source: Aquestive Therapeutics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)